Zodley Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-11-2024
- Paid Up Capital ₹ 0.60 M
as on 15-11-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -10.35%
(FY 2023)
- Profit -12.68%
(FY 2023)
- Ebitda -3.37%
(FY 2023)
- Net Worth 10.52%
(FY 2023)
- Total Assets 2.26%
(FY 2023)
About Zodley Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Madhubala Agarwal and Dharamveer Chaudhary serve as directors at the Company.
- CIN/LLPIN
U24110PB2009PTC033105
- Company No.
033105
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zodley Pharmaceuticals Private Limited offer?
Zodley Pharmaceuticals Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Nutraceuticals, Protein Supplement, Diabetic Medicines, Vitamins, Minerals & Antioxidants.
Who are the key members and board of directors at Zodley Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhubala Agarwal  | Director | 12-Aug-2009 | Current |
| Dharamveer Chaudhary | Director | 12-Aug-2009 | Current |
Financial Performance of Zodley Pharmaceuticals.
Zodley Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.35% decrease. The company also saw a substantial fall in profitability, with a 12.68% decrease in profit. The company's net worth Soared by an impressive increase of 10.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zodley Pharmaceuticals?
In 2023, Zodley Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zorion Drugs And Herbs Private LimitedActive 7 years 3 monthsDharamveer Chaudhary is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zodley Pharmaceuticals?
Unlock and access historical data on people associated with Zodley Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zodley Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zodley Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.